Nat Med . Rapid Isolation and Profiling of a Diverse Panel of Human Monoclonal Antibodies Targeting the SARS-CoV-2 Spike Protein

[tetano]

Nat Med


. 2020 Jul 10.
doi: 10.1038/s41591-020-0998-x. Online ahead of print.
Rapid Isolation and Profiling of a Diverse Panel of Human Monoclonal Antibodies Targeting the SARS-CoV-2 Spike Protein


Seth J Zost ¹ , Pavlo Gilchuk ¹ , Rita E Chen ^{2 3} , James Brett Case ³ , Joseph X Reidy ¹ , Andrew Trivette ¹ , Rachel S Nargi ¹ , Rachel E Sutton ¹ , Naveenchandra Suryadevara ¹ , Elaine C Chen ⁴ , Elad Binshtein ¹ , Swathi Shrihari ³ , Mario Ostrowski ⁵ , Helen Y Chu ⁶ , Jonathan E Didier ⁷ , Keith W MacRenaris ⁷ , Taylor Jones ¹ , Samuel Day ¹ , Luke Myers ¹ , F Eun-Hyung Lee ⁸ , Doan C Nguyen ⁸ , Ignacio Sanz ⁸ , David R Martinez ⁹ , Paul W Rothlauf ^{10 11} , Louis-Marie Bloyet ¹¹ , Sean P J Whelan ^{10 11} , Ralph S Baric ⁹ , Larissa B Thackray ³ , Michael S Diamond ^{2 3 11 12} , Robert H Carnahan ^{13 14} , James E Crowe Jr ^{15 16 17}



Affiliations

• PMID: 32651581
• DOI: 10.1038/s41591-020-0998-x

Abstract

Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date^1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.